6
February 2025
Microsaic Systems
plc
("Microsaic", "Microsaic Systems" or the "Company")
Board
Changes
Microsaic Systems plc (AIM: MSYS),
an international developer and provider of testing solutions for
unique and underserved public health and environmental markets, is
pleased to announce that Dr. Christopher ("Chris") Potts will join
the board as Independent Non-Executive Director with immediate
effect. Bob Moore remains in the role of Executive Chairman and
acting Chief Executive Officer pending the appointment of a new
Non-Executive Chairman as planned and to be announced in due
course.
Dr Chris Potts brings over 20 years
of senior executive and chair experience of international
technology businesses.
He is presently Chair of proSapient
Ltd, a world leading service company based in the UK, with offices
in the US, Canada and Portugal, utilising artificial intelligence
technology to search for and engage experts who can assist in due
diligence processes for leading global management consultancies and
private equity firms.
He is also Chair of Zytronic plc; a
UK based manufacturing company which supplies sophisticated touch
screen technology to a global market. Before that, he was Chair of
Guralp Systems limited, a UK based firm which designs,
manufactures, and installs seismic sensors for customers globally,
for nine years.
Chris's prior CEO experience
includes leading privately owned firms, private equity backed
businesses and divisions of listed public companies. He has a
proven track record of steering manufacturing, software
development, and service-based firms, while managing diverse,
multidisciplinary teams of technical, scientific, and business
leaders.
He has led several large
international corporate transactions. He has also served as a
trustee or non-executive director of three university or
educational institutions.
Academic and research credentials
include a PhD from the University of Cambridge, an MBA from
Cranfield School of Management, and published papers in
international peer-reviewed scientific journals.
Regulatory Disclosures
The following disclosures are
required regarding Chris Potts' appointment to the Board, pursuant
to Schedule Two paragraph (g) of the AIM Rules for
Companies.
Christopher Graeme Potts (aged 68)
is currently, or has during the past five years been, a director of
the following companies:
Current directorships or partnerships
|
Previous directorships or partnerships
|
·
Zytronic plc
·
ProSapient Limited
·
The American University of Bulgaria
|
·
Goodhind Bullard Limited
·
Guralp Systems Limited ("GSL")¹
·
Guralp Finance Limited
·
Guralp Holdings Limited
·
Guralp Systems Inc
·
Moller Institute Limited
·
Guralp Systems GmbH
|
Save as set out above, there is no
further information to be disclosed in accordance with Schedule Two
(g) of the AIM Rules for Companies.
Microsaic Systems plc
Bob Moore, Chief Executive
officer
|
+44 (0) 20 3657
0050
via Turner
Pope
|
|
|
Singer Capital Markets (Nominated Adviser & Joint
Broker)
Alex Bond / Oliver Platts
|
+44 (0) 20 7496
3000
|
|
|
Turner Pope Investments (TPI) Limited (Joint
Broker)
Andy Thacker / James Pope
|
+44 (0) 20 3657
0050
|
About Microsaic Systems Group
Microsaic is highly experienced in the
development, manufacture and supply of microelectronics
instrumentation for markets requiring analytical testing in public
and environmental health markets. The Company has recently acquired
and integrated the assets of Modern Water with Microsaic Systems'
technologies resulting in comprehensive water testing and other
toxic testing capabilities. Microsaic's products and solutions are
commercially available through global markets via a network of
regional and country specific distributors and partners.
¹ The following disclosure in
relation to GSL is considered outside of the scope of Schedule Two,
paragraph (g) of the AIM Rules, Dr. Christopher Potts has not been
subject to any criticism, sanction or penalty in relation to this
matter, but this disclosure is being made in the interests of
transparency.
Dr. Christopher Potts became a director of GSL in on 1
December 2014. In September 2015, Dr. Potts formed suspicions of
corrupt payments having previously been made by GSL to an
individual who had held various positions with an overseas
government-funded research institute and promptly terminated all
contractual and other relationships between GSL and him. Dr Potts
then instructed a firm of solicitors to undertake an internal
review.
That review, instigated by Dr. Potts and certain other
Directors of GSL, led to the company reporting its suspicions on 23
October 2015 to the SFO and to the United States Department of
Justice ("DoJ").
On
22 October 2019, GSL finalised a Deferred Prosecution Agreement
("DPA") with the Serious Fraud Office ("SFO") following a criminal
investigation, under the terms of which GSL was required to
disgorge c. £2.1m to the Court, over a period of up to 5 years from
the date of the DPA. The DoJ did not prosecute the Company but
indicted several former employees, at least one of whom received a
custodial sentence for money laundering offences.
In
the court-approved judgement relating to the DPA, it was noted
that, "the current senior management team of GSL has done all that
it can to remedy the position and to co-operate with prosecuting
authorities in two jurisdictions." It was also noted that, "those
who had taken over the running of the company in 2015 identified
the conduct, instructed outside solicitors to investigate and
self-reported to the SFO."
The conclusion to the DPA judgement, stated that "the company
which has entered the DPA is very different to that which engaged
in the conduct as set out in the statement of facts. Those running
the company are wholly different from those who were in charge at
the time of the relevant conduct. The corporate practices of the
company have changed completely. A rigorous compliance programme is
in place with appropriate provision for regular review
thereof."